<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01416701</url>
  </required_header>
  <id_info>
    <org_study_id>DvitKOL01022011</org_study_id>
    <nct_id>NCT01416701</nct_id>
  </id_info>
  <brief_title>Vitamin D and Chronic Obstructive Lung Disease</brief_title>
  <official_title>Vitamin D and COPD. A Randomised, Double-blind, Placebo-controlled Trial of the Effect of Vitamin D on Withdrawal From Pulmonary Rehabilitation and Exercise Endurance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jorgen Vestbo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect of vitamin D intervention in patients with
      chronic obstructive pulmonary disease (COPD) undergoing rehabilitation.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    It was not possible to enroll the planned amount of subjects. Many patients with chronic
    obstructive pulmonary disease already took large doses of vitamin D.
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Withdrawal from rehabilitation.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Withdrawal will be defined as giving up rehabilitation or delaying any training visit by more than 3 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in walking distance</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in walking distance from week 0 to week 24. Exercise capacity is evaluated using paced walking (Incremental Shuttle Walk Test(ISWT) and Endurance Shuttle Walk Test (ESWT)).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in vitamin D status.</measure>
    <time_frame>52 weeks</time_frame>
    <description>se-25-OHD se-PTH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in calcium metabolic status.</measure>
    <time_frame>52 weeks</time_frame>
    <description>se-calcium se-phosphate se-magnesium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life.</measure>
    <time_frame>52 weeks</time_frame>
    <description>COPD Assessment Test (CAT) and St George Respiratory Questionnaire (SGRQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in status of bone metabolism.</measure>
    <time_frame>52 weeks</time_frame>
    <description>DXA (Dual energy X-ray Absorptiometry) scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in walking distance.</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change in walking distance from week 0 to week 11 and week 52. Exercise capacity is evaluated using paced walking (Incremental Shuttle Walk Test (ISWT) and Endurance Shuttle Walk Test (ESWT)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fat mass and fat free mass.</measure>
    <time_frame>52 weeks</time_frame>
    <description>Whole body DXA scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical activity.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Physical activity at home is measured over a week using an activity sensor (SenseWear Pro armband).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD exacerbations.</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause hospital admissions.</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality.</measure>
    <time_frame>52 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Obstructive Lung Disease</condition>
  <arm_group>
    <arm_group_label>Vitamin D (D3, cholecalciferol)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (cellulose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D (D3, cholecalciferol)</intervention_name>
    <description>Week 0-4: 152 mcg/daily (4 tablets) Week 5-52: 76 mcg/daily (2 tablets)</description>
    <arm_group_label>Vitamin D (D3, cholecalciferol)</arm_group_label>
    <other_name>Bio Vinci Mega D-vitamin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo (cellulose)</intervention_name>
    <description>Week 0-4: 4 tablets daily Week 4-52: 2 tablets daily</description>
    <arm_group_label>Placebo (cellulose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 50 years

          -  Diagnosed COPD with forced expiratory volume in 1 second (FEV1) &lt; 50 % of predicted

          -  Breathlessness relative to MRC dyspnoea grade 3 or more

        Exclusion Criteria:

          -  Patients with known diseases of bone metabolism apart from osteoporosis and patients
             with granulomatous disease

          -  Patients with hyper- or hypocalcemia at inclusion

          -  Patients with cardiovascular or musculoskeletal disease that impacts significantly on
             walking based on the investigator's judgement

          -  Patients with dementia or other mental conditions rendering them unable to understand
             the study information and thus provide informed consent

          -  Patients with terminal disease or known cancer with bone metastases, increasing their
             risk of hypercalcemia

          -  Patients taking more than 20 mcg vitamin D on a daily basis. If a patient takes
             vitamin D below this limit, dose should have been stable 6 months prior to inclusion
             in order to achieve steady-state.

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jørgen Vestbo, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre Universityl Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hvidovre University Hospital, Department of Respiratory Medicine</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Unit, Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2011</study_first_submitted>
  <study_first_submitted_qc>August 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2011</study_first_posted>
  <last_update_submitted>April 8, 2013</last_update_submitted>
  <last_update_submitted_qc>April 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Jorgen Vestbo</investigator_full_name>
    <investigator_title>Prof. DMSc</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Pulmonary rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

